Long-read sequencing for cancer liquid biopsy: advancing precision oncology

1

Liquid biopsy analyzes tumor-derived genetic material in body fluids, providing a minimally invasive approach for cancer diagnosis and monitoring.
2

Long-read sequencing (LRS) technologies, such as SMRT and nanopore sequencing, enhance detection of structural variants and epigenetic modifications.
3

LRS has shown promise in analyzing cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) across various cancer types, including lung and brain cancers.
4

Current challenges for LRS in liquid biopsy include pre-analytical variability, cost, and high computational demands.
5

LRS is positioned to complement multimodal liquid biopsy strategies in precision oncology as sequencing technologies continue to advance.

1